ScandiDos and C-RAD have decided to end the cooperation on the North American market

ScandiDos and C-Rad, two Uppsala-based companies both active in the field of
radiation therapy, have decided to discontinue the sales cooperation on the
North American market. With upcoming introduction of new products from both
companies a partly competitive situation arises. Therefore the sales-cooperation
was terminated.
In June 2013 ScandiDos and C-Rad launched the cooperation on the North American
market. The companies entered into a mutual distribution agreement for the other
company's products.

ScandiDos provide products in the field of dosimetry and quality assurance for
radiation therapy clinics and C-RAD offers products in the field of patient
positioning. The two companies decided to let their respective sales
organizations sell products from both companies to get mutually an increased
presence in sales in North America. ScandiDos’ and C-RADs recent product
developments will lead to an overlapping product offer to the customer. A
competitive situation will arise as soon as the products are released.

ScandiDos and C-RAD will now continue to market and sell via their individual
organizations in North America and focus their resources on their respective
products. Ongoing sales projects which have been developed during the
cooperation will be finalized until end of July.

Görgen Nilsson, CEO, ScandiDos AB

“C-Rad now starts to market their imaging-product in the field of quality
assurance and thereby becomes a provider of downstream dosimetry. This means
that we have to look upon C-Rad as a competitor to ScandiDos. Therefore we
terminate the sales-cooperation in North America.

ScandiDos has a well-functioning organization in US since 6 years with main
-office in Madison conducting sales and giving appreciated support to a
relatively large customer base. We will now focus 100% on our own products on
the North American market.”

Tim Thurn, CEO, C-RAD AB:

“C-RAD is currently in a phase of high growth. With recent product developments
C-RAD will be entering into the dosimetry market. Therewith a competitive
situation between C-RAD and ScandiDos will occur. By ending the cooperation both
companies have the opportunity to market their entire product portfolio on the
important US market. To further develop our success a committed and energetic
team is essential.”
For further information contact:
Görgen Nilsson, CEO ScandiDos AB, Phone +46-18-472 3032, e-mail:
Gorgen.Nilsson@ScandiDos.com
About ScandiDos

ScandiDos has with its product Delta4 phantom positioned itself as a worldwide
leading company in advanced dosimetry and QA (Quality Assurance) in the field of
Radiation Therapy of cancer.

The QA ScandiDos provides ensures that the dose delivery in advanced radiation
therapy e.g. IMRT and VMAT is given to the patient as it was planned.

Delta4 is a platform of products with advanced measuring systems and software
calculations to quality assure the entire treatment from prescription to final
treatment fraction, using unique accuracy and efficiency.

The Delta4 concept also uniquely provides tools to analyze the data and find the
cause of any discrepancy in order to enable fast and accurate correction of the
treatment or treatment plan.

ScandiDos cooperates worldwide with Elekta and Varian and with some 40 local
distributors ScandiDos has installed system in 40 countries.